Puma Biotechnology's officers and directors' statements may have exposed the company to significant civil liability. The company currently faces a class action lawsuit alleging that Puma Biotechnology knew about neratinib's modest health benefits and concealed these facts from the public. On September 30, 2016, U.S. District Judge Andrew J. Guilford denied Puma Biotechnology's motion to dismiss the class action, which may expose the company to millions of dollars in damages, as well as investigatory and litigation costs related to defending the action.
If you currently own stock in Puma Biotechnology and wish to obtain additional information about Schubert Jonckheer & Kolbe's investigation and your legal rights, please contact Dustin Schubert either via email at email@example.com or by telephone at (415) 788-4220, or fill out the form on our website at http://classactionlawyers.com/pumabiotech.
About Schubert Jonckheer & Kolbe
Schubert Jonckheer & Kolbe has extensive experience in prosecuting securities claims, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/puma-biotechnology-inc-shareholder-alert-schubert-firm-investigates-companys-top-executives-300342521.html
SOURCE Schubert Jonckheer & Kolbe LLP